Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

O'Shaughnessy J, Robert N, Annavarapu S, Zhou J, et al. Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study. Breast Cancer Res Treat 2021 Mar 1. pii: 10.1007/s10549-021-06137.
PMID: 33649981


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016